NXC-736 is under clinical development by Nextgen Bioscience and currently in Phase I for Alopecia Areata. According to GlobalData, Phase I drugs for Alopecia Areata have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NXC-736’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NXC-736 overview

NXC-736 is under development for the treatment of nonalcoholic steatohepatitis, transplant rejection, ulcerative colitis and alopecia areata. It is administered by oral route in the form of tablet. The therapeutic candidate acts by inhibiting NLR family pyrin domain containing 3 (NLRP3), S1PR1 and S1PR2.

For a complete picture of NXC-736’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.